Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

Download PDF Copy

Editorial Checklist

Reviewed

RegeneRx Biopharmaceuticals, Inc.Nov 18 2011

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

The Australian patent is for the treatment or prevention of damage due to heart failure and will expire in July, 2026.

The Mexican patent is for the treatment or prevention of damage caused by increased blood flow in the myocardium, commonly called reperfusion injury. It will expire in January, 2026.

RegeneRx has similar patents pending in numerous other countries, including in the U.S., Asia and Europe.

Source:

RegeneRx Biopharmaceuticals, Inc.

Posted in: Medical Condition News | Medical Patent News | Pharmaceutical News

Tags: Biotechnology, Blood, Brain, Cardiology, Dry Eye, Epidermolysis Bullosa, Heart, Heart Failure, Multiple Sclerosis, Nervous System, Stroke, Traumatic Brain Injury

Comments (0)

Download PDF Copy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.